CD274 and neoplasm: Mutation in the 3' UTR region of CD274 gene has been recently reported in hematologic [8] and solid tumors [9] as a potential biomarker for assessing efficacy during immunotherapy, suggesting the rare variants in the UTR region of CD274 gene to guide tumor immunotherapy.